anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
FIELD: molecular biology, biochemistry, immunology. SUBSTANCE: recombinant antibody reacts specifically with protein p55 of Tac-receptor of human interleukin-2 (IL-2). The indicated antibody inhibits binding of IL-2 with IL-2-receptor on human T-cells and shows affinity to IL-2 receptor above 10 8 M -1 . In consists of light and heavy chains and has sites that determine complementarity (CDR s ). Invention proposes also polynucleotides containing a sequence encoding carcass sites and sites determining complementarity of binding with antigen (CDR s ). Also, invention proposes methods of preparing heavy and/or light chains of recombinant antibody. Invention can be used for preparing recombinant DNA and nonimmunogenic monoclonal antibodies for preparing new therapeutic agents. EFFECT: improved method of preparing. 11 cl, 10 dwg, 1 tbl, 5 ex
The protection of the replication fork structure under stress conditions is essential for genome maintenance and cancer prevention. A key signaling pathway for fork protection involves TRPV2-mediated Ca2+ release from the ER, which is triggered after the generation of cytosolic DNA and the activation of cGAS/STING. This results in CaMKK2/AMPK activation and subsequent Exo1 phosphorylation, which prevent aberrant fork processing, thereby ensuring genome stability. However, it remains poorly understood how the TRPV2 channel is activated by the presence of cytosolic DNA. Here, through a genome-wide CRISPR-based screen, we identify TRPM8 channel-associated factor 1 (TCAF1) as a key factor promoting TRPV2-mediated Ca2+ release under replication stress or other conditions that activate cGAS/STING. Mechanistically, TCAF1 assists Ca2+ release by facilitating the dissociation of STING from TRPV2, thereby relieving TRPV2 repression. Consistent with this function, TCAF1 is required for fork protection, chromosomal stability, and cell survival after replication stress.
All study patients will participate in the study for two consecutive transfusion episodes (a transfusion episode is defined as a clinic visit where 2 RBC units are transfused) and will receive an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. Randomization will dictate the order of the transfusion. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
The invention discloses a formula of hair loss preventing and hair fixing essence, which comprises the following raw materials: the formula of No. 1 raw materials: ethanol, water, radix Polygoni Multiflori (Polygonum MULTIFLORUM) root extract, cacumen Platycladi (Platycladus ORIENTALIS) leaf extract, fructus Ligustri Lucidi (Ligustrum LUCIDUM) fruit extract, rhizoma Chuanxiong (Ligusticum CHUANXIONG) root extract, radix Sophorae Flavescentis (Sophora ANGUSTIFOLIA) root extract, radix astragali Mongolici (Astragalus MEMBRANACEUS MONGHOLICUS) extract, flos Carthami (Carthamus TINCTORIUS) flower extract, and herba Morinae Bulleyanae (Morus NIGRA) fruit extract; the formula of No. 2 raw materials: glycerol (glycerol); the formula of No. 3 raw materials: BETAINE (BETAINE); the formula of No. 4 raw materials: PANTHENOL (pantol); the formula of No. 5 raw materials: bis (hydroxymethyl) imidazolidinyl UREA (DIAZOLIDINYL UREA), (daily) perfume (FRAGRANCE). The invention relates to the technical field of hair loss prevention essence formula. The hair loss preventing and hair fixing essence formula solves the problems that the existing hair loss preventing essence formula is inconvenient to stimulate hair follicles to improve scalp conditions and supplement nutrition to hair roots.
Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid. Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Optionally the agents are detoxified. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein. Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein.
Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
The Ustilaginoidea virens -rice pathosystem has been used as a model for flower-infecting fungal pathogens. The molecular biology of the interactions between U. virens and rice, with an emphasis on the attempt to get a deeper comprehension of the false smut fungus's genomes, proteome, host range, and pathogen biology, has been investigated. Meta-QTL analysis was performed to identify potential QTL hotspots for use in marker-assisted breeding. The Rice False Smut (RFS) caused by the fungus Ustilaginoidea virens currently threatens rice cultivators across the globe. RFS infects rice panicles, causing a significant reduction in grain yield. U. virens can also parasitize other hosts though they play only a minor role in its life cycle. Furthermore, because it produces mycotoxins in edible rice grains, it puts both humans and animals at risk of health problems. Although fungicides are used to control the disease, some fungicides have enabled the pathogen to develop resistance, making its management challenging. Several QTLs have been reported but stable gene(s) that confer RFS resistance have not been discovered yet. This review offers a comprehensive overview of the pathogen, its virulence mechanisms, the genome and proteome of U. virens, and its molecular interactions with rice. In addition, information has been compiled on reported resistance QTLs, facilitating the development of a consensus genetic map using meta-QTL analysis for identifying potential QTL hotspots. Finally, this review highlights current developments and trends in U. virens-rice pathosystem research while identifying opportunities for future investigations.
All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
Children with special needs with mobility difficulties use various assistive devices to benefit from the beneficial effects of standing upright and moving. These devices have beneficial effects on improving children's motor skills and increasing their social interaction and participation. In addition, during the use of assistive devices, there are some limitations related to size, weight, usability, mobility, and adaptability to children. Considering these limitations, the Dynamic Scaffolding System (DSS) device was developed. The DSS device aims to position children with moderate to severe mobility impairment vertically (standing and sitting) and to step with support. The aim of the current study was to compare the duration of use of the Dynamic Scaffolding System (DSS) device in children with different levels of motor impairment, to report adverse events during use, and to examine parental satisfaction. One hundred children with special needs (60% cerebral palsy, 40% other diagnoses: genetic, metabolic, neuromuscular diseases) aged between 9 and 108 months (mean 44.94±17.59) and their parents (94% mother, 6% father) who had used the DSS device for at least 6 months were included in the study. Data were collected from the participants via telephone interview. Demographic data such as age, gender, diagnosis, and level of motor impairment were recorded. Children's daily use of the DSS device, any adverse events during use, and parental satisfaction were assessed using the Quebec 2.0 Assistive Technology User Satisfaction Assessment Questionnaire.
The invention relates to stomatology and perfumery, more specifically to curative and prophylactic compositions for the oral cavity care. Said invention also relates to means for sanitation of the oral cavity and can be used for producing curative and prophylactic tooth pastes, gels, liquids for the oral cavity care and other compounds such as chewing gum, gel etc. The inventive composition containing active and inert components acceptable for oral use comprises 0.01-1mass % bromelaine and 1.5-20mass % xylitol in the form of active components. In the preferred embodiment, the bromelaine content ranges from 0.1 to 0.8 mass % and the xylitol within a range better than 2.2-18 mass %. In order to obtain a remineralization effect, the composition contains an anti-caries additive in a quantity of 0.05-3.0 mass %. In the preferred embodiment, the content of said additive ranges from 0.2 to 2.5 mass %. A calcium glycerophosphate and magnesium organic and inorganic salts are preferably used in the form of the mineral anti-caries additive. The use of sodium, potassium, calcium, and magnesium monophosphates in a quantity of 0.5-1.5 mass % in the form of the mineral anti-caries additive is also admissible. The optimal concentration ranges from 0.8 to 1.1 mass %.
Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
The invention relates to a traditional Chinese medicine composition for treating warts. The composition is prepared from arnebia root, isatis root and coix seed. Applications of the composition are also provided. The composition and the applications are advantageous in that the composition has main functions of clearing heat and toxins, drying dampness and removing warts. The composition mainly treats the warts. The warts have symptoms of wind-heat-toxin stagnation by syndrome differentiation of traditional Chinese medicines, and have symptoms such as soybean-shaped, hard, coarse, yellow or red nodules being different in size and higher than skin, red tongue with thin fur, and taut rapid pulse.
BACKGROUND: Non-communicable diseases are highly prevalent among adults living with HIV, emphasizing the need for comprehensive healthcare strategies. However, a dearth of knowledge exists regarding the health systems challenges in managing HIV and non-communicable diseases and the perception of health workers regarding the integrated management of non-communicable diseases during routine HIV care in rural Ugandan settings. This study aims to bridge this knowledge gap by exploring the health system challenges in managing HIV and non-communicable diseases and health workers' perception regarding the integration of non-communicable diseases in routine HIV care in South Central Uganda.
METHODS: In this qualitative study, we collected data from 20 purposively selected key informants from Kalisizo Hospital and Rakai Hospital in South Central Uganda. Data were collected from 15th December 2020 and 14th January 2021. Data were analyzed using a thematic content approach with the help of NVivo 11.
RESULTS: Of the 20 health workers, 13 were females. In terms of work duration, 9 had worked with people living with HIV for 11-15 years and 9 were nurses. The challenges in managing HIV and non-communicable diseases included difficulty managing adverse events, heavy workload, inadequate communication from specialists to lower cadre health workers, limited financial and human resources, unsupportive clinical guidelines that do not incorporate non-communicable disease management in HIV care and treatment, and inadequate knowledge and skills required to manage non-communicable diseases appropriately. Health workers suggested integrating non-communicable disease management into routine HIV care and suggested the need for training before this integration.
CONCLUSION: The integration of non-communicable disease management into routine HIV care presents a promising avenue for easing the burden on health workers handling these conditions. However, achieving successful integration requires not only the training of health workers but also ensuring the availability of sufficient human and financial resources.
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease). Arm A explores the safety and efficacy of nivolumab alone, and Arm B explores the safety and efficacy of nivolumab plus Relatlimib. Patients with recurrent or metastatic esophagogastric cancer are eligible for this study which will enroll patients with limited disease burden and who are Programmed death-1(PD-1) therapy naïve. This will allow for us to assess if systemic ablative radiation (SBRT to multiple metastatic sites plus PD-1/ anti-LAG3) is able to enhance the effectiveness of nivolumab +/- anti-LAG3 or to overcome treatment resistance mechanisms. Patients will be treated with targeted high dose radiation (SBRT) to metastatic lesions as outlined below. One of the lesions which is considered the easiest to biopsy and not causing symptoms will not be radiated so as to obtain tissue for correlative analysis. This lesion will then be re-biopsied approx. 4 weeks after the completion of radiation to the other metastatic sites. If a lesion is causing pain or other symptoms this site will not be chosen as the biopsiable site. The chosen metastatic lesion can then be irradiated at a later date if we do not see disease response in that region. Approximately 21 patients will be enrolled on study with 6 enrolled on Arm A, and 15 enrolled on Arm B.
It is well-known that mitral valve plays an important role in the development of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. In order to further investigate this phenomenon, the following study aims to compare mitral valve geometry indices, as assessed by transthoracic echocardiography, two- and three-dimentional transesophageal echocardiography and mitral valve quantification analysis, and papillary musles' function, as assessed by 2D speckle tracking imaging, in patients with hypertrophic obstructive cardiomyopathy, patients with arterial hypertension and left ventricular hypertrophy and people without structural heart disease. This will provide information on the geometric characteristics of mitral valve that predispose to the development of obstruction. Futhermore, patients with hypertrophic obstructive cardiomyopathy that are eligible for the surgical relief of obstruction will be randomised into four groups according to the modality of intervention. These groups are as follows: 1) isolated extended septal myectomy; 2) extended septal myectomy + edge to edge mitral valve repair; 3) extended septal myectomy + posterior lealfet sliding plasty; 4) extended septal myectomy + secondary chordae transection. After surgery, said indices will be reassessed and the degree of outflow tract obstruction relief noted, in order to elicit which geometrical changes are produced by each type of intervention. Patients will be followed long-term, up to 5 years, in order to define whether the addition of the intervention on mitral valve helps abolish the residual gradient more effectively, and whether it translates into any survival benefit.
The invention discloses a salt formed by combining tris (hydroxymethyl) aminomethane and an acid radical, or an aqueous solution of the salt, which is applied to a medicine for treating hyperuricemia, gout, acute and chronic arthritis, lithiasis in the urinary system and related diseases. The treatment action mechanism is as follows: the trihydroxymethyl aminomethane and uric acid are combined through hydrogen bonds to generate a 'uric acid-trihydroxymethyl aminomethane' combination, so that uric acid crystallization is prevented, and uric acid crystals (stones) are dissolved; meanwhile, the combination of uric acid and macromolecular substances such as blood fat, blood sugar and the like is reduced, and the influence of uric acid on blood fat and blood sugar is reduced. Compared with the existing methods: 1. the three action mechanisms of reducing the intake, 2, inhibiting the endogenous synthesis, 3 and promoting the renal excretion for treating the hyperuricemia can be called as a fourth action mechanism. The present invention may also be referred to as a fourth treatment for hyperuricemia. The problem of crystallization of uric acid and the problem of influence of uric acid on blood fat and blood sugar are solved in a targeted manner. Has definite action mechanism, good curative effect and small side effect.
Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
FIELD: medicine, gastroenterology, pharmacy. SUBSTANCE: invention proposes using taurolidine, taurultam or their combination as an agent used in treatment of mammalian digestive tract diseases caused by Helicobacter pylori, Helicobacter heilmanni or combination of indicated microorganisms. Invention relates also to method for treatment of corresponding diseases and to composition based on combination of taurolidine, taurultam or their combination with preparation that forms protective cover on the patient stomach mucosa and to composition based on combination of taurolidine, taurultam or their combination with inhibitor of proton pump. Invention provides both suppression of growth of indicated campilobacteria and blocking their adhesion with epithelial cells of stomach mucosa that eliminates pathogenicity of microorganisms and ceasing secretion of cytotoxin VacA. EFFECT: valuable medicinal properties of drugs, enhanced effectiveness. 9 cl
Age, weight, and severity of the infection are important factors in determining the proper dosage. In mild to moderate infections, the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day in equally divided doses every 6 hours. For more severe infections this dosage may be doubled. If twice-a-day dosage is desired, one-half of the total daily dose may be given every 12 hours. Doses may also be given three times daily by administering one-third of the total daily dose every 8 hours.

The following dosage schedule is suggested for mild to moderate infections:
CNS stimulants, including JORNAY PM, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. 

Careful observation for digital changes is necessary during JORNAY PM treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for JORNAY PM-treated patients who develop signs or symptoms of peripheral vasculopathy.
The invention discloses a rare earth up-conversion composite nano material for treating tumors, and constructs a near-infrared remote light-controlled up-conversion photodynamic therapy and tumor microenvironment triggerable chemical kinetics cooperative therapy platform to realize the treatment of hypoxic tumorsCan be used for treating diseases. The UCNPs with high efficiency and stable luminescence can convert 980 nm NIR light into 540nm green light, so that HB of a photosensitizer after red shift of an absorption spectrum is excited to carry out a PDT process. Endogenous acidic H in the tumor microenvironment 2 O 2 Hydrolyzed MnO 2 Can realize O 2 The self-sufficiency of the PDT can overcome the tumor hypoxia obstacle and improve the oxygen-dependent treatment efficiency of the PDT. Mn produced by hydrolysis 2+ Can mediate Fenton-like reaction to generate virulent OH, and cause oxidative stress of tumor cells. MnO 2 Can also consume the intracellular antioxidant GSH, reduce OH clearance and improve CDT efficiency. The platform combines the tumor microenvironment response, PDT and CDT for cooperative treatment, improves the treatment efficiency and realizes the effective treatment of the hypoxic tumor.
Ischemic stroke is a leading cause of adult disability and death worldwide. The primary treatment for cerebral ischemia patients is to restore blood supply to the ischemic region as quickly as possible. However, in most cases, more severe tissue damage occurs, which is known as cerebral ischemia/reperfusion (I/R) injury. The pathological mechanisms of brain I/R injury include mitochondrial dysfunction, oxidative stress, excitotoxicity, calcium overload, neuroinflammation, programmed cell death and others. Propofol (2,6-diisopropylphenol), a short-acting intravenous anesthetic, possesses not only sedative and hypnotic effects but also immunomodulatory and neuroprotective effects. Numerous studies have reported the protective properties of propofol during brain I/R injury. In this review, we summarize the potential protective mechanisms of propofol to provide insights for its better clinical application in alleviating cerebral I/R injury.
The study will enroll 4 randomized groups of 30 subjects each for a total of 120 subjects. These groups will be split so that 60 individuals receive the 1.0 mg dose and the other 60 receive the 2.0 mg dose. Every subject will receive a total of 3 injections on Days 0, 28, and 56. Half of each of these groups (n = 30) will receive 2 vaccine injections at Days 0 and 56 (normal saline placebo on Day 28) while the other half will receive 3 vaccine injections at Days 0, 28, and 56. All subjects will receive a booster dose at Day 168 to help assess immunogenicity with this booster dose. All doses will be administered with the TDS-IM device. All subjects will be followed until at least Day 252 (a 12 month follow-up visit may be requested). Subjects will complete post-injection memory aids for 7 days after each injection. There will also be up to 12 alternates enrolled and used to replace any original subject who fails to complete all 3 scheduled primary injections and Day 70 follow-up visit.